Rocket Pharmaceuticals (9IP1) Stock Statistics & Valuation Metrics

Rocket Pharmaceuticals has a market cap or net worth of €273.72M. The enterprise value is €1.22B.

Rocket Pharmaceuticals has 107,737,920 shares outstanding. The number of shares has decreased by -2.65% in one year.

Rocket Pharmaceuticals’s return on equity (ROE) is -0.56 and return on invested capital (ROIC) is -55.77%.

The current PE Ratio of Rocket Pharmaceuticals is -4.61. Rocket Pharmaceuticals’s PEG ratio is -0.30.

In the last 12 months, Rocket Pharmaceuticals had revenue of 0.00 and earned -258.75M in profits. Earnings per share was -2.73.

In the last 12 months, operating cash flow was -208.69M and capital expenditures -4.19M, giving a free cash flow of -212.88M billion.

Rocket Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Rocket Pharmaceuticals upcoming earnings date is Aug 11, 2025, TBA Not Confirmed.

Rocket Pharmaceuticals as a current ratio of 9.30, with Debt / Equity ratio of 4.67%

In the past 12 months, Rocket Pharmaceuticals has paid 0.00 in taxes.

Rocket Pharmaceuticals EV to EBITDA ratio is -3.86, with an EV/FCF ratio of -4.89.

Rocket Pharmaceuticals has €318.16M in cash and marketable securities with $25.35M in debt, giving a net cash position of -€292.81M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Rocket Pharmaceuticals is €9.30, which is 11.43% higher than the current price. The consensus rating is Moderate Buy